Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.

Quest Diagnostics (DGX) Presents New Data on Disease Testing

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.

Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio

SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2023 financial results on Wednesday, July 26, 2023, before the market opens.

Quest Diagnostics to Release Second Quarter 2023 Financial Results on July 26, 2023

SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology.

Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio

Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.

Quest Diagnostics (DGX) Partners to Offer New Testing Service

Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.

Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes

SECAUCUS, N.J. , June 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Global Healthcare Conference.

Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference

The Meta Quest 3 is the successor to the Quest 2 headset that was released in the fall of 2020 at a starting price of $299.

Zuckerberg unveils Meta's newest VR headset days before Apple reveals its own

SECAUCUS, N.J. , June 1, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference.

Quest Diagnostics to Speak at the William Blair 43rd Annual Growth Stock Conference

Quest Diagnostics Incorporated has seen modest growth in recent years, although serial buybacks have increased growth on a per-share basis to attractive percentages. The company has been resilient and diversified and has seen a boom and consequential bust cycle in Covid-19-related testing revenues. With the pandemic fading, the headwind to reported growth should subside, potentially being the trigger for a Quest Diagnostics Incorporated re-rating here.

Quest Diagnostics: Healthier Diagnosis

Quest Diagnostics' revenue and earnings fell in Q1. The company's low payout ratio should support future dividend growth.

Want Growing Passive Income? Consider Buying This Stock

Increase Seen in the General U.S. Workforce Started Same Year First States Legalized Recreational Marijuana Overall Workforce Drug Test Positivity Persisted at Two-Decade High Across All Workers Marijuana and Amphetamines Positivity Climbed in Key Industries SECAUCUS, N.J. , May 18, 2023 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for marijuana following an on-the-job accident increased to its highest level in 25 years in 2022, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

Post-Accident Workforce Drug Positivity for Marijuana Reached 25-Year High in 2022, Quest Diagnostics Drug Testing Index Analysis Finds

SECAUCUS, N.J. , May 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A.

Quest Diagnostics Elects Luis A. Diaz, Jr., M.D.

Accolade

Bio-Rad Laboratories

Sangamo Therapeutics

Sotera Health

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)

The collaboration aims to help physicians improve detection and care of potentially treatable causes of cognitive decline SECAUCUS, N.J. and RALEIGH, N.C.

Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health

Biogen

Eli Lilly

Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.

Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease

Quest Diagnostics Incorporated (DGX) Q1 2023 Earnings Call Transcript.

Quest Diagnostics Incorporated (DGX) Q1 2023 Earnings Call Transcript

First quarter revenues of $2.33 billion, down 10.7% from 2022 First quarter reported diluted earnings per share ("EPS") of $1.78, down 39.0% from 2022; and adjusted diluted EPS of $2.04, down 36.6% from 2022 First quarter base business revenues of $2.21 billion, up 10.0% from 2022 Full year 2023 revenues now expected to be between $8.93 billion and $9.08 billion; reported diluted EPS now expected to be between $7.52 and $8.02; and adjusted diluted EPS expected to be between $8.45 and $8.95 SECAUCUS, N.J. , April 27, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2023.

Quest Diagnostics Reports First Quarter 2023 Financial Results; Updates Guidance for Full Year 2023

Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined with Quest's oncology, genomics and pathology expertise and scale, including solid tumor sequencing, convenient specimen collection and EHR connectivity SECAUCUS, N.J. and BALTIMORE , April 27, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, and Haystack Oncology, an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisions, today announced a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.

Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio

SECAUCUS, N.J., April 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, and NewYork-Presbyterian, one of the nation's largest and most comprehensive academic medical centers, today announced that Quest has completed its previously announced acquisition of select assets of the laboratory services business of NewYork-Presbyterian. Financial details of the transaction were not disclosed.

Quest Diagnostics and NewYork-Presbyterian Complete Laboratory Services Acquisition

Agree Realty

Axis Capital

Caterpillar

Colgate-Palmolive

Erie Indemnity

Farmers & Merchants Bancorp

First Bancorp

H.B. Fuller

Gladstone Investment

Glacier Bancorp

Graham Holdings

Horizon

Intuit

Kaiser Aluminum

Gladstone Land

Lakeland Financial

McCormick

New York Times

Oracle

Bank OZK

Procter & Gamble

Pentair

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of April 16

Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.

Quest Diagnostics (DGX) Advances Access to Transplant Services

SECAUCUS, N.J. , April 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2023 financial results on Thursday, April 27, 2023, before the market opens.

Quest Diagnostics to Release First Quarter 2023 Financial Results on April 27, 2023

ABM Industries

Albany International

Avient Corp

Bristol-Myers

Broadridge Financial

Brady Corporation

Chubb

Comcast

Chesapeake Utilities

Cisco Systems

Dollar General

Eastman Chemical

Evans Bancorp

Getty Realty

Hartford Financial Services Group

Hamilton Lane

H&R Block

International Flavors & Fragrances

Independent Bank

Dividend Champion, Contender, And Challenger Highlights: Week Of April 2

Schwab US Dividend Equity ETF

All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.1% and a median increase of 7.6%.

5 Upcoming Dividend Increases To Start Q2

News for Quest Diagnostics Stock (DGX)